Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Oral Edaravone in ALS
NCT04165824Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Shionogi & Co., Ltd. Primary endpoint: Number of Treatment Emergent Adverse Events at 48 weeks. Started Nov 2019; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04165824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165824.